Education
About Us
Working with TipRanks
Follow Us
Natera (NTRA)
NASDAQ:NTRA
NTRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$83.13 - $183.00
Previous CloseN/A
Volume352.74K
Average Volume (3M)2.12M
Market Cap
$20.43B
Enterprise Value$15.27B
Total Cash (Recent Filing)$945.59M
Total Debt (Recent Filing)$187.12M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
May 07, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding135,186,190
10 Day Avg. Volume2,008,159
30 Day Avg. Volume2,117,443
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)12.04
Price to Cash Flow (P/CF)96.60
P/FCF Ratio94.30
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit14.92
Enterprise Value/Ebitda-105.66
Forecast
1Y Price Target
$197.67Price Target Upside28.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
---
Bulls Say, Bears Say
Bulls Say
Market LeadershipNatera Inc. is a leader in the $20B MRD market with a strong base in NIPT and carrier screening.
Revenue GrowthRevenue was driven by an increase in volume and ASPs, marking the fourth consecutive positive cash flow quarter.
Test Volume GrowthTesting volume showed significant growth with oncology tests increasing by 55%.
Bears Say
Operating ExpensesOpex guidance came in above expectations due to new products and sales channel investments.
Trial ExpensesNTRA plans to spend ~$20M on an FDA enabling trial this year ($40M over 2 years).
---
Ownership Overview
4.83% Insiders
29.07% Mutual Funds
31.96% Other Institutional Investors
15.07% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NTRA FAQ
What was Natera’s price range in the past 12 months?
Natera lowest stock price was $83.13 and its highest was $183.00 in the past 12 months.
What is Natera’s market cap?
Natera’s market cap is $20.43B.
When is Natera’s upcoming earnings report date?
Natera’s upcoming earnings report date is May 07, 2025 which is in 43 days.
How were Natera’s earnings last quarter?
Natera released its earnings results on Feb 27, 2025. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.381 by -$0.029.
Is Natera overvalued?
According to Wall Street analysts Natera’s price is currently Undervalued.
Does Natera pay dividends?
Natera does not currently pay dividends.
What is Natera’s EPS estimate?
Natera’s EPS estimate is -0.64.
How many shares outstanding does Natera have?
Natera has 135,186,190 shares outstanding.
What happened to Natera’s price movement after its last earnings report?
Natera reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.381. Following the earnings report the stock price went down -0.651%.
Which hedge fund is a major shareholder of Natera?
Currently, no hedge funds are holding shares in NTRA
---
Natera Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$197.67 (28.50% Upside)
$197.67 (28.50% Upside)
Blogger Sentiment
Bullish
NTRA Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 23.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.7%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.52%
12-Months-Change
Fundamentals
Return on Equity
-19.42%
Trailing 12-Months
Asset Growth
15.73%
Trailing 12-Months
Company Description
Natera
Natera, Inc. (NTRA) is a global leader in cell-free DNA testing, specializing in genetic testing services that focus on women's health, oncology, and organ health. The company utilizes proprietary technology to develop and commercialize non-invasive tests that help in early detection and management of genetic conditions. Natera's flagship products include Panorama, a non-invasive prenatal test (NIPT), Horizon, a carrier screening test, and Signatera, a test for cancer recurrence monitoring.
---
NTRA Company Deck
---
NTRA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance, significant advancements in product coverage, and successful data initiatives. While there are some challenges, particularly in the immediate financial impact of new legislative measures and product introductions, the overall outlook remains positive with substantial growth opportunities in oncology and women's health.Read More>---
NTRA Stock 12 Month Forecast
Average Price Target
$197.67
▲(28.50% Upside)
Technical Analysis
Best Analysts Covering NTRA
1 Year
1 Year Success Rate
13/15 ratings generated profit
1 Year Average Return
+73.06%
reiterated a buy rating 2 months ago
Copying Matthew Sykes's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +73.06% per trade.
---